Abstract:The baseline platelet count and on‐treatment hepatitis B surface antigen glycan isomer/hepatitis B surface antigen (HBsAgGi/HBsAg) ratio were useful predictors of hepatocellular carcinoma (HCC) development during nucleoside/nucleotide analog (NA) therapy. In addition, it suggests that a combination of on‐treatment HBsAgGi and HBsAg may lead to an increase in the accuracy of predictions of the development of HCC during NA therapy compared with HBsAg alone. Aim A recombinant monoclonal antibody against the hepatitis B surface antigen glycan isomer (HBsAgGi) was newly developed using the O‐glycosylated PreS2 peptide in M‐HBsAg of hepatitis B virus (HBV) genotype C. However, the association between HBsAgGi and the development of hepatocellular carcinoma (HCC) during nucleoside/nucleotide analog (NA) therapy remains unknown. Methods A total of 112 HBV genotype C‐infected patients who were treated with NA were included in this study. We assessed the association between HBV markers, including HBsAgGi and other conventional markers, and the development of HCC during NA therapy. Results Ten patients developed HCC during the follow‐up period. Of the HBV markers, HBsAg (≤3.53 log IU/mL; p = 0.047), HBsAgGi/HBsAg ratio (≥1.10; p = 0.035), and HBV DNA (≤6.3 log copies/mL; p = 0.012) at baseline and HBsAg (≤3.19 log IU/mL; p = 0.033) and HBsAgGi/HBsAg ratio (≥1.09; p = 0.003) at 48 weeks after NA therapy were significantly associated with the development of HCC according to the log rank test. In contrast, no significant association was observed between HBsAgGi and the development of HCC. Multivariate analysis revealed that a platelet count at baseline ≤88 × 103/mm3 (p = 0.026; hazard ratio [HR], 10.577) and an HBsAgGi/HBsAg ratio at 48 weeks after NA therapy ≥1.09 (p = 0.040; HR, 10.099) were independently and significantly associated with the development of HCC. Conclusions Our findings suggest that a combination of on‐treatment HBsAgGi and HBsAg predicts the development of HCC during NA therapy.

Nuclear Antigen Detected in Hepatoma Cell Lines Containing Integrated Hepatitis B Virus DNA

Involvement of Hepatitis B Core-Related Antigen in Viral Genome Integration in Patients With Prior Hepatitis B Virus Infection

[Hepatitis non-A, non-B-associated substance in stool from patients with posttransfusion and sporadic hepatitis]

In situ analysis of hepatitis B virus (HBV) antigen and DNA in HBV-induced hepatocellular carcinoma

[The Expression of Hepatitis C Antigen in Hepatitis and Liver Cancer Tissues].

Total Hepatitis B Core Antigen Antibody, a Quantitative Non-Invasive Marker of Hepatitis B Virus Induced Liver Disease

[Preparation of Monoclonal Antibody Directed Against Hepatitis B Virus X Protein and Detection of Reactive Antigen in Hepatocellular Carcinoma].

Mutations in hepatitis B virus DNA from patients with coexisting HBsAg and anti-HBs.

A Chromogenic In Situ Hybridization (CISH) Assay for Detection of HBV RNA, DNA, and cccDNA in Liver Tissue

Novel fully automated prototype assays for specific detection of phosphorylated and non-phosphorylated Hepatitis B core antigens.

Hepatitis B Virus Pregenomic RNA in Hepatocellular Carcinoma: A Nosological and Prognostic Determinant

Hepatitis B surface antigen glycan isomer is a predictor of the development of hepatocellular carcinoma during nucleoside/nucleotide analog therapy

In Situ Analysis of Intrahepatic Virological Events in Chronic Hepatitis B Virus Infection.

Characterization of Hepatitis B Virus Infection and Viral DNA Integration in Non-Hodgkin Lymphoma.

Localization of CD8+ cells specific for hepatitis B virus surface protein in the liver of immunized mice

Detection of HBsAg in a Clone Derived from the PLC/PRF/5 Human Hepatoma Cell Line

Dectetion of Preneoplastic Markers of Hepatitis B Virus-Associated Hepatocellular Carcinoma

Occult Hepatitis B Virus Infection with Positive Hepatitis B E Antigen

Characterization and Clinical Application of a Monoclonal Antibody to Hepatitis B Virus Large Surface Proteins

Relationship Between Serum Hepatitis B Virus Dna and Surface Antigen with Covalently Closed Circular Dna in Hbeag-Negative Patients

Detection of HBV-cccDNA in Hepatic Cells by in Situ PCR